Recent News

• 11.04.2026 - ImmunityBio Announces First Patients in Europe Treated with ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ
• 10.22.2026 - Jefferies Global Healthcare Conference
• 10.21.2026 - ImmunityBio Announces Database Lock for Registrational Trial of Locally Delivered, Chemotherapy-Free ANKTIVA® Plus BCG in BCG-Naïve Non-Muscle Invasive Bladder Cancer
• 10.16.2026 - ImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC With CIS, With or Without Papillary Tumors
• 10.14.2026 - FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Disease
• 10.08.2026 - ImmunityBio to Participate in the Piper Sandler Virtual Oncology Symposium
• 08.18.2026 - AHNS 2026 International Conference on Head and Neck Cancer
• 08.18.2026 - ASH Annual Meeting
• 08.18.2026 - ESMO Asia
• 08.18.2026 - MaTOS

Recent Filings

• 10.14.2026 - 8-K Current report
• 10.14.2026 - EX-99.1 EX-99.1
• 10.06.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.06.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.05.2026 - 144 Report of proposed sale of securities
• 10.02.2026 - 144 Report of proposed sale of securities
• 08.06.2026 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 08.04.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.04.2026 - 8-K Current report
• 08.04.2026 - EX-99.1 EX-99.1